Jinyu Bio-Technology Co Ltd (SHG:600201) — Market Cap & Net Worth
Market Cap & Net Worth: Jinyu Bio-Technology Co Ltd (600201)
Jinyu Bio-Technology Co Ltd (SHG:600201) has a market capitalization of $1.89 Billion (CN¥12.90 Billion) as of September 21, 2026. Listed on the SHG stock exchange, this China-based company holds position #6420 globally and #1281 in its home market, demonstrating a -2.57% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jinyu Bio-Technology Co Ltd's stock price CN¥11.73 by its total outstanding shares 1099927826 (1.10 Billion). Also see 600201 asset base for a full breakdown of the balance sheet.
Jinyu Bio-Technology Co Ltd Market Cap History: 2015 to 2026
Jinyu Bio-Technology Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $2.97 Billion to $1.89 Billion (-1.89% CAGR). Also see 600201 cash flow conversion for how efficiently the company converts equity into cash flow.
Jinyu Bio-Technology Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jinyu Bio-Technology Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 600201 live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.74x
Jinyu Bio-Technology Co Ltd's market cap is 1.74 times its annual revenue
Latest Price to Earnings (P/E) Ratio
24.23x
Jinyu Bio-Technology Co Ltd's market cap is 24.23 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.57 Billion | $1.52 Billion | $644.54 Million | 1.70x | 3.99x |
| 2017 | $3.67 Billion | $1.90 Billion | $870.09 Million | 1.93x | 4.22x |
| 2018 | $2.54 Billion | $1.90 Billion | $754.47 Million | 1.34x | 3.37x |
| 2019 | $2.93 Billion | $1.13 Billion | $221.04 Million | 2.60x | 13.25x |
| 2020 | $3.28 Billion | $1.58 Billion | $406.20 Million | 2.07x | 8.07x |
| 2021 | $2.58 Billion | $1.78 Billion | $382.29 Million | 1.45x | 6.76x |
| 2022 | $1.44 Billion | $1.53 Billion | $210.66 Million | 0.94x | 6.84x |
| 2023 | $1.73 Billion | $1.60 Billion | $283.63 Million | 1.08x | 6.11x |
| 2024 | $1.10 Billion | $1.26 Billion | $108.99 Million | 0.88x | 10.13x |
| 2025 | $2.43 Billion | $1.40 Billion | $100.11 Million | 1.74x | 24.23x |
Competitor Companies of 600201 by Market Capitalization
Companies near Jinyu Bio-Technology Co Ltd in the global market cap rankings as of September 21, 2026. Review 600201 tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Jinyu Bio-Technology Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Jinyu Bio-Technology Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Jinyu Bio-Technology Co Ltd's market cap moved from $2.97 Billion to $ 1.89 Billion, with a yearly change of -1.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.89 Billion | -22.16% |
| 2025 | CN¥2.43 Billion | +119.68% |
| 2024 | CN¥1.10 Billion | -36.30% |
| 2023 | CN¥1.73 Billion | +20.30% |
| 2022 | CN¥1.44 Billion | -44.21% |
| 2021 | CN¥2.58 Billion | -21.19% |
| 2020 | CN¥3.28 Billion | +11.86% |
| 2019 | CN¥2.93 Billion | +15.29% |
| 2018 | CN¥2.54 Billion | -30.83% |
| 2017 | CN¥3.67 Billion | +42.75% |
| 2016 | CN¥2.57 Billion | -13.29% |
| 2015 | CN¥2.97 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 20th, 2026 the market cap of Jinyu Bio-Technology Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.89 Billion USD |
| MoneyControl | $1.89 Billion USD |
| MarketWatch | $1.89 Billion USD |
| marketcap.company | $1.89 Billion USD |
| Reuters | $1.89 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Jinyu Bio-Technology Co Ltd
Jinyu Bio-technology Co., Ltd. engages in the research and development, production, and sale of veterinary biological products in China and internationally. The company's products focus on preventing porcine mycoplasmal pneumonia, pseudorabies, highly pathogenic avian influenza, brucellosis, and other Class I, II, and III animal diseases. It also provides pig vaccines, swine foot-and-mouth diseas… Read more